Obesity Development Articles & Analysis
17 news found
Mouse models for T2DM study is generated by feeding mice a high-fat or high-sugar diet or genetically modifying mice to develop obesity and insulin resistance. These models matter a lot in type 2 diabetes research. Different from T2DM mouse models, GDM mouse models involve feeding mice a high-fat or high-sugar diet during pregnancy or genetically modifying mice ...
Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows: Title: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, ...
BE is associated with an increased risk of developing esophageal adenocarcinoma (EAC). The survival rate for invasive EAC is very poor with less than 10% survival at 5 years. Risk factors for BE include chronic GERD, male gender, obesity and smoking. Once a person develops BE, currently only invasive treatment options are available. ...
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of ...
(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association ...
His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. ...
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of ...
“Initiation of the Phase 2 MOMENTUM obesity trial marks an important milestone in the development of pemvidutide,” stated Dr. ...
“With more than one-third of U.S. adults considered to be obese and with very limited non-surgical weight-loss options, the market potential for the ReShape Procedure is significant,” said Michael Mashaal, MD of HealthCor Partners Management, L.P. ...
While an estimated 50 million Americans are classified as obese with a BMI of 30-40, many neither qualify for nor want surgery, creating a significant unmet need for additional treatment options. ...
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. ...
New risks and new understanding As people live longer, the main causes of premature death and disability have become non-communicable, ’lifestyle’-related conditions, such as obesity, cardiovascular diseases, diabetes, and cancer. In so far as these problems may be linked to environmental conditions, it has become increasingly important to address all these issues ...
New research indicates that bisphenol-A, or BPA, may be responsible for the increasing rates of obesity and diabetes in the developed world. Past studies have linked the chemical to obesity and diabetes (as well as a greater risk of cancer, heart disease, and behavioral problems in young children), but now findings published in the journal PLoS ...
Earlier studies have shown that ANA can actually develop many years before the clinical appearance of autoimmune diseases, such as type 1 diabetes, lupus, and rheumatoid arthritis. ...
The grant will help us to improve access for these essential primary care services and develop a pediatric obesity program at both Albany and Troy ...
The National Toxicology Program (NTP) is hosting this workshop on Jan. 11-13, 2011, because there is a growing body of research showing that chemicals in our environment may be contributing to diabetes and obesity worldwide, and that chemical exposures need to be considered along with nutrition and diet. Six chemical classes will be discussed at the workshop, including 1) arsenic and other ...
In addition, children will be screened for asthma, birth defects, diabetes, injury susceptibility, obesity and physical and mental development disorders. The outcomes of pregnancies, such as preterm delivery, also will be evaluated. From that information, scientists can look at how certain factors alone or in combination affect pregnancy outcomes, child ...